413 related articles for article (PubMed ID: 16259571)
1. Current pharmacotherapy for acromegaly: a review.
Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
[TBL] [Abstract][Full Text] [Related]
2. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
4. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
6. [Contemporary options and perspectives in the treatment of acromegaly].
Marek J
Cas Lek Cesk; 2014; 153(3):131-6. PubMed ID: 24968290
[TBL] [Abstract][Full Text] [Related]
7. [Advances in the treatment of acromegaly].
Krysiak R; Okopień B; Marek B
Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
[TBL] [Abstract][Full Text] [Related]
8. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
12. New perspectives in the medical treatment of acromegaly.
Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
[TBL] [Abstract][Full Text] [Related]
13. New medical therapies of acromegaly.
Maffezzoni F; Frara S; Doga M; Mazziotti G; Giustina A
Growth Horm IGF Res; 2016; 30-31():58-63. PubMed ID: 27745780
[TBL] [Abstract][Full Text] [Related]
14. Primary medical therapy for acromegaly.
Sheppard MC
Clin Endocrinol (Oxf); 2003 Apr; 58(4):387-99. PubMed ID: 12641619
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological approach to the treatment of acromegaly.
Ezzat S
Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
[TBL] [Abstract][Full Text] [Related]
16. Pegvisomant: Balance after 10 years.
Bernabeu I; Marazuela M
Endocrinol Nutr; 2015 Oct; 62(8):363-5. PubMed ID: 26242927
[No Abstract] [Full Text] [Related]
17. Current therapy and drug pipeline for the treatment of patients with acromegaly.
Kumar SS; Ayuk J; Murray RD
Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
[TBL] [Abstract][Full Text] [Related]
19. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
20. How effective are current therapies for acromegaly?
Freda PU
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]